Blockade of CSF1R with PLX3397 induced clinical regression in patients and decreased the intratumoral accumulation of immunosuppressive macrophages, thus confirming the validity of TAMs as a therapeutic target in cancer therapy [70, 71]. The gene discussed is CSF1R; the disease is cancer.